Evaluating safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens
Wafik S. El-Deiry, Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, shared a post on X:
“Here’s a trial in leukemia MRD: AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.
A peptide vaccine approach has been under investigation (2023) against a cancer driver (mutant RAS) in pancreatic cancer during minimal residual disease. AI needs to prove what it adds as the drivers of cancer are well known by experts. Why $500B?”
AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients
Authors: Susanne Jung, Annika Nelde, Yacine Maringer, Monika Denk, Lisa Zieschang, Christine Kammer, Melek Özbek, Peter Martus, Christopher Hackenbruch, Alexander Englisch, Jonas S Heitmann, Helmut R Salih, Juliane S Walz.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023